Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jun 1;213(11):1678-85.
doi: 10.1093/infdis/jiw023. Epub 2016 Jan 27.

A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants

George Armah  1 , Kristen D C Lewis  2 , Margaret M Cortese  3 , Umesh D Parashar  3 , Akosua Ansah  4 , Lauren Gazley  2 , John C Victor  2 , Monica M McNeal  5 , Fred Binka  6 , A Duncan Steele  2
Affiliations
Clinical Trial

A Randomized, Controlled Trial of the Impact of Alternative Dosing Schedules on the Immune Response to Human Rotavirus Vaccine in Rural Ghanaian Infants

George Armah et al. J Infect Dis. .

Erratum in

  • Armah et al (J Infect Dis 2016; 213:1678-85).
    [No authors listed] [No authors listed] J Infect Dis. 2016 Oct 1;214(7):1127. doi: 10.1093/infdis/jiw265. Epub 2016 Aug 2. J Infect Dis. 2016. PMID: 27485358 Free PMC article. No abstract available.

Abstract

Background: The recommended schedule for receipt of 2-dose human rotavirus vaccine (HRV) coincides with receipt of the first and second doses of diphtheria, pertussis, and tetanus vaccine (ie, 6 and 10 weeks of age, respectively). Alternative schedules and additional doses of HRV have been proposed and may improve vaccine performance in low-income countries.

Methods: In this randomized trial in rural Ghana, HRV was administered at ages 6 and 10 weeks (group 1), 10 and 14 weeks (group 2), or 6, 10, and 14 weeks (group 3). We compared serum antirotavirus immunoglobulin A (IgA) seroconversion (≥20 U/mL) and geometric mean concentrations (GMCs) between group 1 and groups 2 and 3.

Results: Ninety-three percent of participants (424 of 456) completed the study per protocol. In groups 1, 2, and 3, the IgA seroconversion frequencies among participants with IgA levels of <20 U/mL at baseline were 28.9%, 37.4%, and 43.4%, respectively (group 1 vs group 3, P = .014; group 1 vs group 2, P = .163). Postvaccination IgA GMCs were 22.1 U/mL, 26.5 U/mL, and 32.6 U/mL in groups 1, 2, and 3, respectively (group 1 vs group 3, P = .038; group 1 vs group 2, P = .304).

Conclusions: A third dose of HRV resulted in increased seroconversion frequencies and GMCs, compared with 2 doses administered at 6 and 10 weeks of age. Since there is no correlate of protection, a postmarketing effectiveness study is required to determine whether the improvement in immune response translates into a public health benefit in low-income countries.

Clinical trials registration: NCT015751.

Trial registration: ClinicalTrials.gov NCT01575197.

Keywords: developing countries; immunization schedules; immunogenicity; infant; randomized controlled trial; rotavirus; rotavirus vaccines; vaccines.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Study profile. Abbreviations: PPE, per-protocol evaluation; SAE, serious adverse event.
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Rotavirus vaccines WHO position paper. Wkly Epidemiol Rec 2007; 82:285–96. - PubMed
    1. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:136–41. - PubMed
    1. Armah GE, Breiman RF, Tapia MD et al. . Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine 2012; 30(suppl 1):A86–93. - PubMed
    1. Armah GE, Kapikian AZ, Vesikari T et al. . Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period. J Infect Dis 2013; 208:423–31. - PMC - PubMed
    1. Binka FN, Anto FK, Oduro AR et al. . Incidence and risk factors of paediatric rotavirus diarrhoea in northern Ghana. Trop Med Int Health 2003; 8:840–6. - PubMed

Publication types

Associated data